Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Financial Performance and Strategy news
(page 17)
12 November 2025
RWE Reports Strong Q3 2025 Financials, Continues Growth Investments
Adjusted EBITDA hits €3.5B; net income €1.3B. Renewable capacity grows to 38.7 GW. 2025 guidance and 2030 targets confirmed.
12 November 2025
Brenntag Q3 2025 Financial Results
Brenntag reports Q3 2025 EBITA of 243M EUR, initiates cost-saving measures, and launches a strategic review to align with market needs and improve efficiency.
11 November 2025
Ercros Reports EUR 4M EBITDA, EUR 41M Losses
Weak demand, high energy costs, and competition impact results. Cost reduction plan on track. Solid liquidity. Awaiting EU support. Bondalti takeover bid approved with conditions.
11 November 2025
BASF Plans Frankfurt Listing for Agricultural Solutions, Introduces New Management Board
Agricultural Solutions aims for IPO readiness by 2027, led by Livio Tedeschi. BASF will retain majority ownership, focusing on growth, innovation, and customer focus.
11 November 2025
Equinor Transfers Peregrino Operatorship to PRIO
Equinor sold a 40% stake in Brazil's Peregrino field to PRIO for USD 2.33 billion, transferring operatorship. Equinor continues as a non-operated partner for the remaining 20% stake.
10 November 2025
Genmab Plans $2.5B Note Offering and $2B Loan for Merus Acquisition
Genmab will use proceeds from notes and loans to fund its Merus acquisition, with notes secured by assets and subject to covenants restricting debt and asset sales.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
7 November 2025
Gunvor Group Secures $2.395 Billion Sustainability-Linked Credit Facility
The facility includes two tranches, supports ESG goals, and involves multiple banks. It refinances existing credit and offers a $400M Accordion Option.
7 November 2025
Fluor Q3 2025 Financial Results
Q3 share repurchases hit $70M; new awards $3.3B. Backlog at $28.2B. Strong cash flow of $286M. EPS, EBITDA, cash flow guidance raised. NuScale investment to be monetized by Q2 2026.
7 November 2025
MOL Group Revises 2025 EBITDA Guidance Amid Strong Q3 Results
Q3 profit stable at USD 503 mn. Upstream steady, downstream boosted by refining margins. Consumer Services grew, Circular Economy Services faced seasonal challenges. Guidance reviewed.
7 November 2025
MOL Group Q3 2025 Earnings Report
Profit before tax stable at USD 503 mn. Upstream steady, downstream improved, consumer services grew. Circular economy services faced challenges. Transformation strategy continues.
7 November 2025
Arkema Q3 2025 Financial Results
Arkema reports €2.2B sales, €310M EBITDA, and €78M net income. Focus on cost-cutting, innovation, and strategic growth amid challenging market conditions.
6 November 2025
Air Products Fiscal 2025 Results Summary
Fiscal 2025 saw adjusted EPS of $12.03, with a $2.9B operating income. Q4 adjusted EPS was $3.39. Fiscal 2026 EPS guidance is $12.85-$13.15, with $4B in capital expenditures expected.
6 November 2025
Solvay Q3 2025 Financial Results
Q3 2025 saw a 6.8% sales drop, €232M EBITDA, €117M free cash flow, and €1.7B net debt. 2025 outlook confirmed with €880-930M EBITDA and €300M free cash flow.
6 November 2025
PureCycle Technologies Q3 2025 Update
Record production, expanded product portfolio, and increased sales pipeline. Ironton compounding to boost capacity. Thailand project progresses. €40M EU grant application accepted.
6 November 2025
Fluor to Monetize Remaining Stake in NuScale
Fluor will convert Class B units to Class A shares and monetize them by Q2 2026, with agreed restrictions to maintain NuScale's equity value.
6 November 2025
Trinseo Q3 2025 Financial Results and Outlook
Net loss of $110M, negative free cash flow of $38M. Plans to cease virgin MMA in Italy, close polystyrene in Germany, aiming for $30M profitability improvement.
6 November 2025
Huntsman Q3 2025 Earnings Report
Q3 2025 saw a net loss of $25M, adjusted EBITDA of $94M, and free cash flow of $157M. Dividend cut by 65% to $0.35 annually. Restructuring aims for $100M savings by 2026.
6 November 2025
Novo Nordisk and U.S. Administration to Lower GLP-1 Costs and Expand Access
Novo Nordisk to lower semaglutide prices in 2026, expand Medicare Part D coverage, and expects a slight negative impact on global sales growth.
6 November 2025
Gunvor USA Refinances $2.8 Billion Credit Facility with Expanded Lender Group
The facility includes $2.11B one-year, $700M two-year tranches, and a $500M accordion. It was oversubscribed, adding four new banks, enhancing liquidity for energy commodities.
6 November 2025
Lilly and U.S. Government Expand Access to Obesity Drugs
Medicare beneficiaries to access obesity drugs at $50/month. LillyDirect offers self-pay options. FDA approval pending.
6 November 2025
Genmab Reports Q3 2025 Financial Results
Revenue up 21% to $2.66B. Proposed Merus acquisition. FDA priority review for epcoritamab. Rina-S gets Breakthrough Therapy Designation. Operating profit rose to $1.007B.
6 November 2025
Veolia: Q3 2025 Financial Highlights
Strong Q3 2025 results: 3.2% revenue growth, 5.4% EBITDA rise, €2.3bn investments, and controlled debt. Confident in meeting annual objectives.
6 November 2025
ENGIE 9M 2025 Financial Results
Strong earnings and cash flow; FY 2025 guidance at upper range. Growth in renewables, PPAs, and flexible assets. EBIT down 7.3% due to lower energy prices. Solid balance sheet maintained.
6 November 2025
Uniper on Track for 2025 Earnings Forecast
Uniper's nine-month earnings align with expectations, despite lower figures. Cash position strong, carbon emissions reduced, and EU remedy progress made. 2025 forecast reaffirmed.
6 November 2025
Lanxess Faces Challenging Q3 2025 Market Conditions
Revenue and EBITDA decline due to weak demand and geopolitical issues. Cost reductions planned. Net debt stable. Full-year EBITDA guidance at lower range.
6 November 2025
Heidelberg Materials Reports Q3 Growth, Confirms 2025 Outlook
Q3 results up 5%, operating margin at 25.9%. Transformation Accelerator boosts savings. CCS projects advance, with evoZero cement deliveries starting. 2025 outlook remains positive.
5 November 2025
MOL Group Calls for Unified European Industrial Strategy
MOL Group urges Europe to adopt a unified industrial policy to enhance competitiveness, reduce energy costs, and streamline regulations for sustainable growth.
5 November 2025
Novo Nordisk Reports 12% Sales Growth in DKK, 15% at CER, and R&D Advances in First Nine Months of 2025
Operating profit rose 5% in DKK, 10% at CER. Obesity care sales up 37%. FDA approved Wegovy® for MASH. Novo Nordisk to acquire Akero Therapeutics. Full-year sales growth forecast at 8-11% CER.
4 November 2025
Merck Partners with Blackstone for Sac-TMT Development Funding
Merck receives $700M from Blackstone for sac-TMT development, retaining control over its progress and commercialization.
4 November 2025
Evonik's Q3 2025 Performance Decline
Q3 2025 saw a 22% EBITDA drop due to weak demand and lower sales. Revenue fell 12%. Efficiency programs are on track, but demand is expected to stay weak through year-end.
← Previous
Next →
